206 related articles for article (PubMed ID: 37310170)
1. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
2. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.
Fan F; Ghosh S; Powell R; Roszik J; Park Y; Sobieski M; Sorokin A; Stephan C; Kopetz S; Ellis LM; Bhattacharya R
PLoS One; 2023; 18(3):e0281063. PubMed ID: 36952536
[TBL] [Abstract][Full Text] [Related]
3. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
5. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
7. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
11. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
12. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
Ziemke EK; Dosch JS; Maust JD; Shettigar A; Sen A; Welling TH; Hardiman KM; Sebolt-Leopold JS
Clin Cancer Res; 2016 Jan; 22(2):405-14. PubMed ID: 26369631
[TBL] [Abstract][Full Text] [Related]
14. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
17. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
20. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O; O'Connor CM; Kulesskiy E; Sangodkar J; Aakula A; Izadmehr S; Yetukuri L; Yadav B; Padzik A; Laajala TD; Haapaniemi P; Momeny M; Varila T; Ohlmeyer M; Aittokallio T; Wennerberg K; Narla G; Westermarck J
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
